

The World Market for Medicaments Containing Penicillins or Streptomycins or Their Derivatives in Dosage Form or Retail Packings: A 2024 Global Trade Perspective

<https://marketpublishers.com/r/W763D5DDDC7EN.html>

Date: May 2023

Pages: 237

Price: US\$ 795.00 (Single User License)

ID: W763D5DDDC7EN

Abstracts

This report was created for strategic planners, international executives, and import/export managers who are concerned with the market for medicaments containing penicillins or streptomycins or their derivatives in dosage form or retail packings. With the globalization of this market, managers can no longer be contented with a local view. Nor can managers be contented with out-of-date statistics that appear several years after the fact. Professor Philip M. Parker, the Chair Professor of Management Science at INSEAD, has developed a methodology, based on macroeconomic and trade models, to estimate the market for medicaments containing penicillins or streptomycins or their derivatives in dosage form or retail packings for those countries serving the world market via exports or supplying from various countries via imports. He does so for the current year based on a variety of key historical indicators and econometric models.

'Medicaments containing penicillins or streptomycins or their derivatives in dosage form or retail packings' as a category is defined in this report following the definition given by the United Nations Statistics Division Classification Registry using the Standard International Trade Classification, Revision 3 (SITC, Rev. 3). The SITC code that defines 'medicaments containing penicillins or streptomycins or their derivatives in dosage form or retail packings' is 54213.

Contents

1 METHODOLOGY

1.1 OUR APPROACH

2 THE WORLD MARKET

2.1 EXPORTS

2.1.1 THE WORLD MARKET: MEDICAMENTS CONTAINING PENICILLINS OR STREPTOMYCINS OR THEIR DERIVATIVES IN DOSAGE FORM OR RETAIL PACKINGS EXPORT SUPPLIES IN 2024

2.2 IMPORTS

2.2.1 THE WORLD MARKET: IMPORTED MEDICAMENTS CONTAINING PENICILLINS OR STREPTOMYCINS OR THEIR DERIVATIVES IN DOSAGE FORM OR RETAIL PACKINGS IN 2024

3 EXPORTS

3.1 AFRICA: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS OR STREPTOMYCINS OR THEIR DERIVATIVES IN DOSAGE FORM OR RETAIL PACKINGS IN 2024

3.1.1 EXECUTIVE SUMMARY

3.1.2 ALGERIA

3.1.3 BENIN

3.1.4 COTE D'IVOIRE

3.1.5 EGYPT

3.1.6 KENYA

3.1.7 MAURITIUS

3.1.8 MOROCCO

3.1.9 SENEGAL

3.1.10 SOUTH AFRICA

3.1.11 TANZANIA

3.1.12 TUNISIA

3.2 ASIA: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS OR STREPTOMYCINS OR THEIR DERIVATIVES IN DOSAGE FORM OR RETAIL PACKINGS IN 2024

3.2.1 EXECUTIVE SUMMARY

3.2.2 BANGLADESH

- 3.2.3 CHINA
- 3.2.4 HONG KONG
- 3.2.5 INDIA
- 3.2.6 INDONESIA
- 3.2.7 JAPAN
- 3.2.8 MALAYSIA
- 3.2.9 SINGAPORE
- 3.2.10 SOUTH KOREA
- 3.2.11 TAIWAN
- 3.2.12 THAILAND
- 3.2.13 VIETNAM

3.3 EUROPE: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS OR STREPTOMYCINS OR THEIR DERIVATIVES IN DOSAGE FORM OR RETAIL PACKINGS IN 2024

- 3.3.1 EXECUTIVE SUMMARY
- 3.3.2 AUSTRIA
- 3.3.3 BELARUS
- 3.3.4 BELGIUM
- 3.3.5 BULGARIA
- 3.3.6 CROATIA
- 3.3.7 CYPRUS
- 3.3.8 DENMARK
- 3.3.9 ESTONIA
- 3.3.10 FINLAND
- 3.3.11 FRANCE
- 3.3.12 GERMANY
- 3.3.13 GREECE
- 3.3.14 HUNGARY
- 3.3.15 ICELAND
- 3.3.16 IRELAND
- 3.3.17 ITALY
- 3.3.18 KAZAKHSTAN
- 3.3.19 LATVIA
- 3.3.20 LITHUANIA
- 3.3.21 MACEDONIA
- 3.3.22 MALTA
- 3.3.23 NORWAY
- 3.3.24 POLAND
- 3.3.25 PORTUGAL

- 3.3.26 ROMANIA
- 3.3.27 RUSSIA
- 3.3.28 SLOVAKIA
- 3.3.29 SLOVENIA
- 3.3.30 SPAIN
- 3.3.31 SWEDEN
- 3.3.32 SWITZERLAND
- 3.3.33 THE CZECH REPUBLIC
- 3.3.34 THE NETHERLANDS
- 3.3.35 THE UNITED KINGDOM
- 3.3.36 UKRAINE

3.4 LATIN AMERICA: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS OR STREPTOMYCINS OR THEIR DERIVATIVES IN DOSAGE FORM OR RETAIL PACKINGS IN 2024

- 3.4.1 EXECUTIVE SUMMARY
- 3.4.2 ARGENTINA
- 3.4.3 BOLIVIA
- 3.4.4 BRAZIL
- 3.4.5 CHILE
- 3.4.6 COLOMBIA
- 3.4.7 COSTA RICA
- 3.4.8 ECUADOR
- 3.4.9 EL SALVADOR
- 3.4.10 GUATEMALA
- 3.4.11 HONDURAS
- 3.4.12 MEXICO
- 3.4.13 PANAMA
- 3.4.14 PARAGUAY
- 3.4.15 PERU
- 3.4.16 URUGUAY
- 3.4.17 VENEZUELA

3.5 NORTH AMERICA & THE CARIBBEAN: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS OR STREPTOMYCINS OR THEIR DERIVATIVES IN DOSAGE FORM OR RETAIL PACKINGS IN 2024

- 3.5.1 EXECUTIVE SUMMARY
- 3.5.2 BARBADOS
- 3.5.3 CANADA
- 3.5.4 CUBA
- 3.5.5 THE DOMINICAN REPUBLIC

3.5.6 THE UNITED STATES

3.6 OCEANIA: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS OR STREPTOMYCINS OR THEIR DERIVATIVES IN DOSAGE FORM OR RETAIL PACKINGS IN 2024

3.6.1 EXECUTIVE SUMMARY

3.6.2 AUSTRALIA

3.6.3 FIJI

3.6.4 NEW ZEALAND

3.7 THE MIDDLE EAST: EXPORT SUPPLIES OF MEDICAMENTS CONTAINING PENICILLINS OR STREPTOMYCINS OR THEIR DERIVATIVES IN DOSAGE FORM OR RETAIL PACKINGS IN 2024

3.7.1 EXECUTIVE SUMMARY

3.7.2 IRAN

3.7.3 ISRAEL

3.7.4 JORDAN

3.7.5 KUWAIT

3.7.6 LEBANON

3.7.7 OMAN

3.7.8 PAKISTAN

3.7.9 SAUDI ARABIA

3.7.10 SYRIA

3.7.11 THE UNITED ARAB EMIRATES

3.7.12 TURKEY

3.7.13 UZBEKISTAN

4 IMPORTS

4.1 AFRICA: MEDICAMENTS CONTAINING PENICILLINS OR STREPTOMYCINS OR THEIR DERIVATIVES IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024

4.1.1 EXECUTIVE SUMMARY

4.1.2 ALGERIA

4.1.3 BENIN

4.1.4 BOTSWANA

4.1.5 BURKINA FASO

4.1.6 BURUNDI

4.1.7 CAMEROON

4.1.8 CAPE VERDE

4.1.9 COTE D'IVOIRE

4.1.10 EGYPT

- 4.1.11 ETHIOPIA
- 4.1.12 GUINEA
- 4.1.13 MADAGASCAR
- 4.1.14 MALAWI
- 4.1.15 MAURITANIA
- 4.1.16 MAURITIUS
- 4.1.17 MOROCCO
- 4.1.18 MOZAMBIQUE
- 4.1.19 NAMIBIA
- 4.1.20 NIGER
- 4.1.21 NIGERIA
- 4.1.22 RWANDA
- 4.1.23 SENEGAL
- 4.1.24 SIERRA LEONE
- 4.1.25 SOUTH AFRICA
- 4.1.26 TANZANIA
- 4.1.27 THE DEMOCRATIC REPUBLIC OF THE CONGO
- 4.1.28 UGANDA
- 4.1.29 ZAMBIA
- 4.1.30 ZIMBABWE

4.2 ASIA: MEDICAMENTS CONTAINING PENICILLINS OR STREPTOMYCINS OR THEIR DERIVATIVES IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024

- 4.2.1 EXECUTIVE SUMMARY
- 4.2.2 BRUNEI
- 4.2.3 CHINA
- 4.2.4 HONG KONG
- 4.2.5 INDIA
- 4.2.6 INDONESIA
- 4.2.7 JAPAN
- 4.2.8 MACAU
- 4.2.9 MALAYSIA
- 4.2.10 MONGOLIA
- 4.2.11 NEPAL
- 4.2.12 SINGAPORE
- 4.2.13 SOUTH KOREA
- 4.2.14 SRI LANKA
- 4.2.15 TAIWAN
- 4.2.16 THAILAND
- 4.2.17 THE PHILIPPINES

4.2.18 VIETNAM

4.3 EUROPE: MEDICAMENTS CONTAINING PENICILLINS OR STREPTOMYCINS OR THEIR DERIVATIVES IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024

4.3.1 EXECUTIVE SUMMARY

4.3.2 ALBANIA

4.3.3 AUSTRIA

4.3.4 BELARUS

4.3.5 BELGIUM

4.3.6 BOSNIA AND HERZEGOVINA

4.3.7 BULGARIA

4.3.8 CROATIA

4.3.9 CYPRUS

4.3.10 DENMARK

4.3.11 ESTONIA

4.3.12 FINLAND

4.3.13 FRANCE

4.3.14 GEORGIA

4.3.15 GERMANY

4.3.16 GREECE

4.3.17 HUNGARY

4.3.18 ICELAND

4.3.19 IRELAND

4.3.20 ITALY

4.3.21 KAZAKHSTAN

4.3.22 LATVIA

4.3.23 LITHUANIA

4.3.24 LUXEMBOURG

4.3.25 MACEDONIA

4.3.26 MALTA

4.3.27 MOLDOVA

4.3.28 NORWAY

4.3.29 POLAND

4.3.30 PORTUGAL

4.3.31 ROMANIA

4.3.32 RUSSIA

4.3.33 SLOVAKIA

4.3.34 SLOVENIA

4.3.35 SPAIN

4.3.36 SWEDEN

4.3.37 SWITZERLAND

4.3.38 THE CZECH REPUBLIC

4.3.39 THE NETHERLANDS

4.3.40 THE UNITED KINGDOM

4.3.41 UKRAINE

4.4 LATIN AMERICA: MEDICAMENTS CONTAINING PENICILLINS OR STREPTOMYCINS OR THEIR DERIVATIVES IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024

4.4.1 EXECUTIVE SUMMARY

4.4.2 ARGENTINA

4.4.3 BELIZE

4.4.4 BOLIVIA

4.4.5 BRAZIL

4.4.6 CHILE

4.4.7 COLOMBIA

4.4.8 ECUADOR

4.4.9 EL SALVADOR

4.4.10 GUATEMALA

4.4.11 GUYANA

4.4.12 HONDURAS

4.4.13 MEXICO

4.4.14 NICARAGUA

4.4.15 PANAMA

4.4.16 PARAGUAY

4.4.17 PERU

4.4.18 SURINAME

4.4.19 URUGUAY

4.5 NORTH AMERICA & THE CARIBBEAN: MEDICAMENTS CONTAINING PENICILLINS OR STREPTOMYCINS OR THEIR DERIVATIVES IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024

4.5.1 EXECUTIVE SUMMARY

4.5.2 BARBADOS

4.5.3 BERMUDA

4.5.4 CANADA

4.5.5 JAMAICA

4.5.6 ST. LUCIA

4.5.7 THE BAHAMAS

4.5.8 THE DOMINICAN REPUBLIC

4.5.9 THE UNITED STATES

4.6 OCEANIA: MEDICAMENTS CONTAINING PENICILLINS OR STREPTOMYCINS OR THEIR DERIVATIVES IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024

4.6.1 EXECUTIVE SUMMARY

4.6.2 AUSTRALIA

4.6.3 FIJI

4.6.4 FRENCH POLYNESIA

4.6.5 NEW CALEDONIA

4.6.6 NEW ZEALAND

4.6.7 PALAU

4.6.8 TONGA

4.7 THE MIDDLE EAST: MEDICAMENTS CONTAINING PENICILLINS OR STREPTOMYCINS OR THEIR DERIVATIVES IN DOSAGE FORM OR RETAIL PACKINGS IMPORTS IN 2024

4.7.1 EXECUTIVE SUMMARY

4.7.2 ARMENIA

4.7.3 AZERBAIJAN

4.7.4 BAHRAIN

4.7.5 ISRAEL

4.7.6 JORDAN

4.7.7 KUWAIT

4.7.8 LEBANON

4.7.9 OMAN

4.7.10 PAKISTAN

4.7.11 QATAR

4.7.12 TURKEY

4.7.13 YEMEN

5 DISCLAIMERS, WARRANTIES, AND USER AGREEMENT PROVISIONS

5.1 DISCLAIMERS & SAFE HARBOR

5.2 ICON GROUP INTERNATIONAL, INC. USER AGREEMENT PROVISIONS

I would like to order

Product name: The World Market for Medicaments Containing Penicillins or Streptomycins or Their Derivatives in Dosage Form or Retail Packings: A 2024 Global Trade Perspective

Product link: <https://marketpublishers.com/r/W763D5DDDC7EN.html>

Price: US\$ 795.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/W763D5DDDC7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

